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Introduction
Cyclin dependent kinases (CDKs) are a group of protein kinases
which regulate different stages of the eukaryotic cell cycle [1–4].
CDKs are also involved in the control of gene transcription, the
processes that integrate extracellular and intracellular signals for
the coordination of the cell cycle in response to environmental
change, and apoptosis [2,5,6]. Activation of CDKs usually occurs
via phosphorylation of specific threonine residues by the CDK-
activating kinase and binding to a cyclin protein. CDK4 plays a
central role in the regulation of the G0–G1 phase of the cell and is
required for the G1/S phase transition. CDK4 inactivates the
retinoblastoma protein (pRb) by phosphorylation. pRb is a
negative regulator of the E2F family of transcription factors [7],
hence phosphorylation of pRb results in the release of transcrip-
tion factors which activate the expression of the S-phase genes.
This process enables the cell to pass through the restriction point
and results in the onset of the S-phase [7–9]. Cell cycle regulators
are frequently mutated in human cancers and due to their central
role in G1 regulation CDKs offer attractive targets for therapeutic
inhibition [10–12]. The work of Yu et al. [13] and Landis et al. [14]
suggests that inhibition of CDK4 might benefit patients with
ErbB-2 initiated breast cancers [12]. The CDK4/CyclinD1
complex as an anti-cancer drug target has been further validated
in MCF-7 breast cancer cells [15].
More than 20 small molecule inhibitors for CDKs are in clinical
trials (for recent reviews see [16–19]). For example, Flavopiridol
(Alvocidib) is in clinical development for the treatment of different
metastatic cancers [20–22]. R-Roscovitine (Seliciclib, CYC202)
inhibits CDK2, CDK7 and CDK9 [23] and is also in clinical
trials. To avoid side effects, high selectivity is desirable, though
difficult to achieve as the ATP binding site of the human kinome is
well conserved [24,25]. Recently, selective inhibitors for CDK4
have gained substantial interest [26,27]. For example the orally
active small molecule PD0332991, which induces G1 arrest in
primary myeloma cells, prevents tumor growth by specific
inhibition of CDK4/6 and is now in Phase 2 clinical trials
[28,29]. The natural compound fascaplysin (Figure 1), originally
isolated from the sponge Fascaplysinopsis Bergquist [30], is a kinase
inhibitor with enticing selectivity for CDK4 (IC50,0.4 mM)
relative to the close homolog CDK2 (45% sequence identity,
IC50,500 mM), and also shows approximately eightfold selectivity
over CDK6 (68% sequence identity, IC50,3.4 mM) [31].
Approximating the dissociation constant KD with IC50 and using
the relation DG0 = 2RTlnKD, the difference in the free energy of
binding between the CDK4/fascaplysin and CDK2/fascaplysin
complexes can be calculated to 4.2 kcal/mol. Considering the
close structural similarity of the active sites of CDK2, CDK4 and
CDK6, and the relatively small size (Mw = 306.75) and rigid
structure of fascaplysin, the observed selectivity is remarkable.
Chemically, fascaplysin is a planar, aromatic compound with no
freely rotatable single bonds. It comprises five condensed rings, the
central ring includes a positively charged imminium nitrogen. An
indol-NH and a carbonyl can act as H-bond donor and H-bond
acceptor, respectively. The H-bond donor and H-bond acceptor in
fascaplysin are oriented in parallel spaced at ,2.6 Å, a feature
shared with other kinase inhibitors. The fascaplysin framework has
been used to synthesise a series of selective CDK4 inhibitors [31–
37], though in most cases selectivity was partially lost in the re-
design process. So what are the features that could explain the
remarkable selectivity of fascaplysin? There is a considerable
amount of structural information on CDKs available to help
addressing this question. More than 100 CDK2 structures in
complex with small molecules are deposited in the protein
databank. However, compared to CDK2, structural information
on CDK6 and CDK4 with inhibitors bound is scarce, in fact the
first CDK4 structures have only been published recently [38,39].
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Most residues in the active sites of CDK2, CDK4 and CDK6 are
remarkably conserved (Figure 2). A key difference is the presence
of a histidine residue in CDK4/6 (His95CDK4 and His100CDK6)
while CDK2 comprises a phenylalanine (Phe82) in the equivalent
position. The His95CDK4/His100CDK6 side-chain is in a position
where it potentially can donate or accept a H-bond from an
inhibitor. Other differences are in Val96CDK4 and Val101CDK6
corresponding to Leu83CDK2. This residue is capable of forming
H-bonds to inhibitors with both backbone NH and carbonyl
group, but as its side chain is pointing away from the binding site
and is not in direct contact with inhibitors the Val/Leu variation
appears to be less relevant for selectivity. Other differences in the
binding site are residues Thr120CDK4 and Thr107CDK6, these
threonines correspond to Lys89CDK2. The negatively charged
residues Asp97CDK4 and Asp102CDK6 have His84CDK2 in the
equivalent position, and finally glutamate Glu144CDK4 is corre-
sponding to Gln131CDK2 and Gln149CDK6 – the latter being the
only position where CDK4 and CDK6 have different residues.
Interestingly, in all three of these positions CDK4 gains a negative
charge relative to CDK2. The potential role of charge as a
determinant of CDK4 inhibitor specificity has been pointed out
originally by McInnes et al. [40] and more recently by
Mascarenhas et al. [41]. In this work, we have studied this
example of charge-determined protein-ligand interactions using a
variety of methods from the molecular modelling and drug design
fields.
The binding of inhibitors to protein receptors with high affinity
and specificity is central to structure-based drug design applica-
tions. The quest for the calculation of binding affinities remains
one of the main goals of modern computational biophysical
methods [42–48]. The most accurate methods for calculating
binding free energies are based on molecular dynamics simulations
which predict the physical properties of the protein-ligand
complexes based on atomistic structural models. The energetic
consequences of small structural changes in inhibitor complexes
have been successfully studied using thermodynamic integration
[49–54]. An added benefit of TI calculations, as compared to
empirical ligand docking algorithms is that the former include
accurate estimates of binding entropy as well as enthalpy, based on
rigorous statistical thermodynamics. In this work, we specifically
address the contribution of the positive charge of fascaplysin (FAS,
see Figure 1A) to selectivity by applying thermodynamic integra-
tion calculations. In silico, fascaplysin can be modified easily by the
iso-electronic substitution of the positively charged nitrogen to a
charge neutral carbon atom, resulting in a compound, which for
clarity and simplicity we refer to as carbofascaplysin (CRB, indolo-
[1,2-c]-fluorene-9-one, see Figure 1B). By calculating the energetic
effect of this substitution for the protein-inhibitor complexes of
both CDK2 and CDK4, we can quantify the impact of the positive
charge of fascaplysin on its specificities towards CDK2 and
CDK4.
Methods
Structure preparation, homology modelling and ligand
docking
The X-ray crystal structure of CDK2 in its active form (PDB-
ID: 1FIN [55]) was used as starting structure for molecular
modelling. For CDK4 ligand docking, molecular dynamics
simulations and free energy calculations a different strategy was
employed. As the five published X-ray structures for CDK4
[38,39] have sections missing and are in an inactive state, a
‘hybrid’ model was constructed in modeller v9.1 [56]. In this
‘hybrid’ model the core of the structure is based on the
experimentally solved CDK4 structure 2W96, but information
from CDK2 (PDB-ID: 1FIN) is used for missing regions and the
positioning of the activation loop. ProSa-web [57] and WhatCh-
eck [58] were used for model validation. The coordinates of the
‘hybrid model’ are provided as supporting information (File S1).
The inhibitor fascaplysin (FAS) and the hypothetical compound
‘carbofascaplysin’ (CRB) were built in Hyperchem 8.0 [59], and
energy minimised prior to docking. Ligand docking calculations
were performed in GOLD v4.1 [60] using the ChemScore scoring
function with the binding site defined with a radius of 12 Å around
the backbone-N of Leu83 for CDK2 and Val96 for CDK4.
PyMOL and VMD were used for molecular visualisation. [61,62]
Molecular dynamics simulations
All molecular dynamics simulations were performed using the
Amber 10 package [63] with the ff99SB [64] force field for
proteins and GAFF [65] for ligands. RESP partial charges for the
two ligands FAS and CRB were derived using GAUSSIAN03 [66]
at the HF/6-31G* theory level and the antechamber program.
CDK2 and CDK4 were solvated in a cubic solvent box so that the
distance between every solute atom and the box boundary was at
least 12 Å and neutralised by adding counter ions. Water
molecules were treated using the TIP4P-Ew water model, a re-
parameterization of TIP4P [67] with Ewald summation [68]; five
buried crystal waters for CDK2 (PDB-ID 1FIN) and four crystal
waters present in equivalent positions in CDK4 were kept in the
simulations. Before the simulations the systems were energy
minimized, initially by steepest descent followed by conjugate
gradient minimization. Then the energy-minimised complexes
were equilibrated by 50 ps heating from 0 K to 300 K followed by
50 ps density equilibration, both with weak restraints for all
protein residues (2.0 kcal/mol Å22) and 500 ps constant pressure
equilibration. Production runs were run for 5 ns with 2 fs time
steps. For all simulations the SHAKE algorithm was used to
constrain bonds between hydrogens and heavy atoms [69],
Langevin dynamics were used for temperature control. Amber
Figure 1. Molecular structures of fascaplysin (FAS) and
‘‘carbofascaplysin’’ (CRB). Fascaplysin (A) is a natural product from
the sponge Fascaplysinopsis Bergquist. Isoelectronic substitution of the
positively charged nitrogen with a carbon atom leads to an electrically
neutral derivative (B), which for the ease of discussion we refer to as
‘‘carbofascaplysin’’.
doi:10.1371/journal.pone.0042612.g001
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tools were used for the analysis of the MD runs, for example the
presence or absence of H-bonds was tested using the ptraj hbond
command with default settings (heavy atom distance , = 3.0 Å,
donor-H-acceptor angle . = 135u)
Thermodynamic Integration. Thermodynamic integration
(TI) estimates the free energy changes between two states A and B
by coupling them via an additional, non spatial coordinate lambda
(l) [70]. TI simulations were carried out for transformation of
CRB to FAS in CDK2, CDK4 and water. Linear mixing of the
potential functions V0 and V1 was used, where V0 and V1
correspond to the potential function for the CRB (l= 0) and FAS
(l= 1) states, respectively. Hence, the combined potential function
V(l) is a function of the perturbation variable l and can be
described as V(l) = (12l) V0+l V1. Since mainly electrostatic
changes were studied, it was not necessary to use soft core
potentials for simulation stability, as e.g. in [71]. Note that with
this TI setup, the total system charge changes during a single
transformation step, while overall charge neutrality for the
thermodynamic cycle is of course maintained. Charge-change TI
calculations involve some additional practical challenges when
compared to charge neutral ones, as electrostatic interactions are
strong and long-ranged, leading to potential convergence prob-
lems. Nevertheless, the PME long-range electrostatics treatment
used here allows for simulations of such net-charge changes [72].
The alternative of simultaneously generating/removing a counter
ion for an overall charge-neutral transformation poses equally
large sampling problems and was avoided here, as is commonly
done in similar studies [73,74]. The thermodynamic integration
simulations were run for 19 l-points/windows (l= 0.05 to
l= 0.95, 5 ns each window). Each 5 ns simulation was divided
into 25 steps of 200 ps. For each step the dV/dl integral was
solved numerically by computing the weighted average of 19
evenly spaced dV/dl values (0.05, 0.10, … 0.95). l-points were
weighted by 0.05 each, with the exception of l= 0.05 and
l= 0.95, which were weighted at 0.075 to extrapolate to the end
points. Linear extrapolation and the trapezoid rule were used for
integration. DDG0 for the relative stabilisation of CRB/FAS in
CDK4/CDK2 were calculated as illustrated in Fig. 3.
Results and Discussion
Homology modelling and ligand docking
CDK4 had escaped structural characterisation by X-ray
crystallography for a long time, but in 2009 Day et al. and
Takaki et al. achieved a major breakthrough and solved its
structure in complex with cyclin D1 [38] and cyclin D3 [39],
respectively. These experimentally determined CDK4 structures
are proposed to represent an intermediate, not fully activated state
Figure 2. Active site conservation in CDK2, CDK4 and CDK6. (A) Structural overlay of active site residues for CDK2 (green, PDB-ID: 1FIN), CDK4
(blue, PDB-ID: 2W96) and CDK6 (red, PDB-ID: 1G3N). (B) Corresponding sequence alignment of the active site residues, the colour scheme is as in (A).
doi:10.1371/journal.pone.0042612.g002
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[38,39] and none of the as yet published structures contains a
small molecule inhibitor in the ATP binding site. Before
experimentally determined CDK4 structures became available,
CDK4 homology models based on experimentally determined
structures of CDK 2 and/or CDK6 were commonly used for
computational studies such as ligand docking e.g. [34,75–77] and
molecular dynamics simulations [78–80]. Most small molecule
CDK4 inhibitors are competitive inhibitors for ATP [81] and
target the active form of CDK4. Hence, CDK4 homology models
representing the active form still have been used in recent ligand
docking studies, despite the availability of experimentally deter-
mined CDK4 structures. [41,82] To take advantage of the new X-
ray structures we opted for a ‘hybrid model’ strategy for studying
the binding behaviour and selectivity of fascaplysin. The core of
the ‘hybrid model’ for CDK4 was built using the CDK4 structure
2W96 as template, but the modelling strategy also made use of an
active form CDK2 structure (PDB-ID: 1FIN) for modelling the T-
loop and to impose an active conformation on the C-helix of
CDK4. ProSa-Web Z-scores for the ‘hybrid model’ and the
CDK4 and CDK2 templates are 27.84, 27.96 and 27.12,
respectively, indicating that the modelling strategy has not
introduced any significant packing problems. The rmsd between
the active form ‘hybrid model’ and the experimentally determined
CDK4 structure (PDB-ID: 2W9F) is 1.5 Å, this is close to the
1.2 Å found for comparing the active (PDB-ID: 1FIN) and inactive
form (PDB-ID: 2R3I) of CDK2. FAS and CRB were docked into
both, CDK2 and CDK4, using the GOLD package. GOLD treats
ligands as fully flexible and allows the user to assign flexibility to a
limited set of receptor residues. The best-scoring docking poses for
all four systems investigated show key features known from
experimentally determined CDK2/inhibitor X-ray structures such
as hydrogen bonding in the hinge region. FAS and CRB docking
poses are characterised by two H-bonds involving the backbone
NH and carbonyl of the hinge residues Leu83CDK2 and
Val96CDK4. No significant difference was found in the docking
scores of both compounds with both CDK2 and CDK4 (Chem-
Scores are in the range of 29 to 31 for CDK2, and 31 to 34 for
CDK4, respectively). So while the ligand docking study generates
typical kinase inhibitor binding poses, it can not explain why
fascaplysin preferably binds to CDK4 rather than CDK2.
A key difference between the CDK2 and CDK4 poses involves
the equivalent residues His95CDK4 and Phe82CDK2. In principle
three different ‘species’ of His95CDK4 have to be considered:
His95CDK4 could have a positively charged imidazole side chain
and there are two uncharged species with either Nd or Ne of the
imidazole ring bearing a hydrogen. We did not consider a
positively charged imidazole side chain as this would unfavourably
interact with the positively charged fascaplysin. However, alter-
native positioning of hydrogens in His95CDK4 (Nd-H and Ne-H)
was considered in the ligand docking process. ChemScores were
by a small margin higher for the His95CDK4Nd-H/fascaplysin
complex (33.4 compared to 31.3 for His95CDK4Ne-H/fascaplysin
complex) indicating a slight preference for the side-chain
conformation in which the Nd-hydrogen of the imidazol ring
forms an additional H-bond to the carbonyl of FAS and CRB,
respectively. This conformation is different from the His95
conformation found in the experimentally determined CDK4
structures, but such a conformational change could occur upon
ligand binding, when the alternative His95CDK4 side chain
conformation is stabilised by the interaction with the inhibitor
(Figure 4A). The idea of His95 as a key player for CDK4
specificity is supported by the notion that CDK6 also has a
histidine residue in the equivalent position. Any energetic
contribution of the additional His95-Nd H-bond to the free
energy of binding should also feature in CDK6, and indeed the
IC50 of CDK6/fascaplysin is, while being ,8 times higher than
CDK4/fascaplysin, still ,100 times lower than CDK2/fascaply-
sin. However, there is a problem with this notion, as if correct, the
interaction in question should occur for most inhibitors, essentially
for any ligand that forms a H-bond with the backbone NH of
Val96CDK4. If His95CDK4 was indeed the key to the observed
fascaplysin CDK4 specificity we would expect this to be rather
generic feature, rendering most CDK inhibitors more specific for
CDK4 as CDK2. This is however not the case and hence it is
unlikely that the difference between His95CDK4 and Phe82CDK2
can account fully for the differential binding of fascaplysin.
The inaccuracy of docking scoring functions for estimating free
energies of binding is a major short coming of typical ligand
docking approaches [83–85]. To obtain more accurately calculat-
ed values for free energies of binding thermodynamic integration
was used. A key feature of fascaplysin is its positive charge.
Docking scoring functions are limited in accounting for long-range
electrostatic interactions; Thermodynamic Integration however
describes long-range electrostatic interactions more accurately as
the Particle Mesh Ewald method for calculating electrostatic
energy terms also incorporates orientation polarisation effects
(conformational response to charge). The Thermodynamic Inte-
gration approach was used to specifically address the role of charge
as a determinant of CDK4 inhibitor selectivity comparing the
charge stabilisation in CDK2/CRB-.CDK2/FAS and His95 Ne-
H CDK4/CRB-.CDK4/FAS complexes [40,41]. To better
account for protein flexibility in response to inhibitor binding a
series of six 5 ns molecular dynamics simulation was performed.
The comparison between runs with all four inhibitor-protein
complexes, FAS and CRB as inhibitors, and CDK2 and CDK4
(both His95 conformers) as receptors, allows the investigation of
conformational change in response to changes of charge of
inhibitors.
Molecular dynamics simulations
Before endeavouring on TI runs the systems corresponding to
the l= 0 and l= 1 endpoints, i.e., CDK2/fascaplysin and CDK2/
carbofascaplysin, CDK4-His95CDK4-Ne-H/carbofascaplysin and
CDK4-His95CDK4-Ne-H/fascaplysin, and for comparison CDK4-
His95CDK4-Nd-H/fascaplysin and CDK4-His95CDK4-Nd-H/car-
bofascaplysin were tested for stability (Figure 5). The average rmsd
(compared to the energy minimised starting structure) over 5 ns
CDK2 simulations is less than 2 Å for both runs, the average rmsd
for the respective CDK4 simulations is slightly higher. This higher
value is not unexpected as the CDK4 structure used for
simulations is the ‘hybrid model’ as described in the materials
Figure 3. Thermodynamic scheme for calculating the contri-
bution of inhibitor charge to the free energy difference in
CDK4/fascaplysin and CDK2/fascaplysin complexes. The ener-
getic contribution of inhibitor charge to specificity is calculated as
difference from two independent steps, the transformation of the
CDK4/carbofascaplysin complex to CDK4/fascaplysin and the transfor-
mation of the CDK2/carbofascaplysin complex to CDK2/fascaplysin.
doi:10.1371/journal.pone.0042612.g003
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and methods section while a experimentally determined high
resolution X-ray structure was used for CDK2. It is however lower
or similar to rmsds that have been reported in MD simulations
using CDK4 homology models previously [41,78–80]. Also, in
comparison to CDK2 the CDK4 structure contains a flexible poly-
Glycin loop comprising seven glycines (residues 42–48) not present
in CDK2. These residues display relatively high Ca-RMSF values
(Figure 5C) and contribute to the higher average rmsd.
Buried waters are often a concern in molecular dynamics
simulations. If they are not transferred from an experimental
structure they are often missed when generating the water box.
Nine water molecules from the CDK2 X-ray structure (PDB ID:
1FIN) were kept for the MD simulations based on their
‘‘conservation’’ across a set of 21 CDK2 inhibitor structures with
a resolution of 1.8 Å or better. Inherently, such an approach is
more difficult for the CDK4 hybrid model, but based on the
CDK4 structures solved by Day et al. [38] four buried water
molecules were included in the CDK4 simulations. Compared to
preliminary simulations which were not using waters from the
experimental structures, the inclusion of these waters enhanced the
stability of the simulations for both, CDK2 and CDK4 simulations
(data not shown).
The ligand docking poses for fascaplysin and carbofascaplysin in
CDK2 and CDK4 suggest that all four binding modes are rather
similar with both ligands forming two hydrogen bonds to
backbone carbonyl and NH of Val96CDK4 and Leu83CDK2,
respectively. Molecular dynamics simulations allow studying these
binding poses over time to give a dynamic picture. (Figure 6). The
two H-bonds to the backbone are present in 97%, 100% and
100% of the simulation snapshots in CDK2/FAS, CDK4-
His95CDK4-Nd-H/FAS, and CDK4-His95CDK4-Ne-H/FAS, re-
spectively. The six simulations also allow addressing the question
of the involvement of specific residues in the selectivity of
fascaplysin to CDK4 by comparing residues which are different
in CDK2 and CDK4 in the four simulations. The substitution of
Phe82CDK2 with His95CDK4 in the equivalent position of CDK4 is
one of the key differences in the active site. Ligand docking
suggests that the side chain of His95CDK4 can form an additional
polar interaction between with FAS and CRB, while Phe82CDK2
cannot play such a role. Monitoring the H-bonding between in
CDK4/FAS and CDK4/CRB, reveals that indeed this takes
place, but only in approximately 46% (CDK4/FAS) and 28%
(CDK4/CRB) of the simulation time (Figure 6E).
Other residues of interest for CDK4 selectivity, originally
proposed by McInnes et al, are Thr102CDK4 and Glu144CDK4
where the corresponding CDK2 residues are Lys89CDK2 and
Gln131CDK2 in CDK2 [40]. For both residues the formal charge
in CDK2 is increased by one. The positive charge of Lys89 in
CDK2 could have a destabilising effect on binding of FAS in
CDK2, and hence contribute to the different binding properties of
CDK2 and CDK4. Interestingly, the average distances between
Lys89-NZ and FAS-N2, and Lys89-NZ and CRB-C0 are 11.0 Å
and 9.7 Å, respectively. The approximately 1.3 Å shorter distance
in the CDK2/CRB complex indicates a conformational response
of Lys89CDK2 to the positive fascaplysin charge (Figure 6F).
Similarly, for the negatively charged residues Glu144CDK4 and
Asp97CDK4 (corresponding to His84CDK2) conformational change
to minimize the distance between FAS and the negatively charged
side chains could occur. Monitoring the distances between OE1
and OE2 of Glu144CDK4, OD1 and OD2 of Asp97CDK4, and N2
and C0 of FAS and CRB, in all four CDK4 simulations does not
support this idea. While the six molecular dynamics simulations
allow monitoring structural differences potentially associated with
differential binding, they do not provide quantitative information
for this phenomenon.
Thermodynamic Integration
Despite substantial progress in ligand docking one of the major
limitations remains the inaccuracy of the scoring functions used for
estimating binding energies. For a quantitative treatment of
binding energies, computationally more accurate (and therefore
computationally more expensive) methods are required. A method
particularly well suited to calculate differences rather than absolute
values of free energies of binding is thermodynamic integration. TI
is best used in situations where small changes in structure correlate
with relatively substantial changes in the free energy of binding.
The preferential binding of fascaplysin to CDK4 with roughly
4.2 kcal/mol difference in the free energies of binding between the
CDK4/fascaplysin and CDK2/fascaplysin complexes studied in
this work clearly falls into this category. The role of positive charge
on inhibitors for CDK4 specificity relative to CDK2 has been
emphasized by McInnes et al. based on a two-unit increase in the
formal charge of the binding pocket of CDK2 relative to CDK4
Figure 4. Predicted binding modes for the fascaplysin/CDK4 and the fascaplysin/CDK2 complexes. The predicted binding modes for
CDK4 (A) and CDK2 (B) show two hydrogen bonds between NH and carbonyl groups of fascaplysin and the backbone carbonyl and NH of Val96 in
CDK4 and of Leu83 in CDK2, respectively. In the CDK4/fascaplysin binding mode an additional hydrogen bond between the Nd-H of the His95CDK4
imidazole side chain and fascaplysin is possible.
doi:10.1371/journal.pone.0042612.g004
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[40]. Such electrostatic interactions are long ranged and sensitive
to large scale conformational motions, therefore extensive MD
simulations need to be conducted to accurately capture their effect.
To avoid these difficulties, TI studies are often limited to charge
neutral transformations [71,86]. In order to specifically quantify
the effect of the positive charge of fascaplysin on differential
binding to CDK2 and CDK4, the ‘energetic cost’ of mutating a
neutral carbon atom (l= 0) into a positively charged nitrogen
(l= 1) was calculated in the inhibitor complexes with CDK2
(DG0CDK2) and CDK4 (DG
0
CDK4) using thermodynamic integra-
tion. The difference (DDG0) of these two TI calculations, DG0CDK2
and DG0CDK4, quantifies the energetic contribution for selectivity
that can be attributed to the positive fascaplysin charge (Figure 3).
The His95-Ne-H conformer was chosen for the CDK4 TI
simulations, so we do not account for any contribution of a
possible His95-Nd-H hydrogen bond to fascaplysin and its
potential effect on selectivity in these simulations. Hence, the
change in free energy we derive from our TI Dsimulations is a
reflection of the differential stabilisation of the positive fascaplysin
charge The TI simulations were run for 19 values of l for 5 ns
each. These runs combined results from 25 data points (repre-
senting 200 ps windows each) for both, DG0CDK4 and DG
0
CDK2,
respectively (Figure 7). The free energy for the transformation of
CRB into FAS in the CDK2 and CDK4 complexes is subject to
fluctuations, but both the curves are clearly separated all the time.
Total DG0CDK4, the free energy for the CRB to FAS transforma-
tion in the CDK4 complex is 23.260.4 kcal/mol compared to
24.660.4 kcal/mol for DG0CDK2 in the CDK2 complex (errors
from badge averaging). The effect of the positive charge in
fascaplysin (or more precisely, the isoelectronic substitution of a
neutral carbon with a positively charged nitrogen) is different in
CDK2 and CDK4. In relative terms the accommodation of the
positive charge is less costly in CDK4 than in CDK2. The positive
charge on fascaplysin contributes with a DDG0 of 1.460.6 kcal/
mol to preferential binding to CDK4, corresponding to a factor of
ca. 10 in terms of KD. While this result is not fully explaining the
extraordinary difference in binding properties, it is clear that the
positive inhibitor charge contributes substantially to the selectivity
of fascaplysin to CDK4. This has important implications for the
design of fascaplysin derived CDK4 inhibitors, a positive charge
should be kept in derivatives. Interestingly, the highly specific
CDK4 inhibitor PD0332991 [27] bears a tertiary amine and
hence also a positive charge. It may achieve, at least partially, its
specificity also via differential stabilisation of the positive charge.
Figure 5. 5 ns MD simulations for CDK4 and CDK2 complexed with fascaplysin and carbofascaplysin. (A) Comparison of backbone rmsd
(relative to the energy minimised starting structure) as a function of time for the CDK4/fascaplysin (red) and CDK4/carbofascaplysin (black)
simulations (B) Comparison of rmsd (relative to the energy minimised starting structure) for the CDK2/fascaplysin (red) and CDK2/carbofascaplysin
(black) simulations. (C) Ca RMSF values for the simulations shown in (A). The peak for residues 42–48 corresponds to a flexible poly-glycine region not
present in CDK2 (D) Ca RMSF values for the in the simulations shown in (C).
doi:10.1371/journal.pone.0042612.g005
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Figure 6. Binding of fascaplysin and carbofascaplyin in CDK4 and CDK2. (A) Distances between the carbonyl oxygen (black), and amide
hydrogen (red) of V96CDK4 and the indoyl hydrogen and carbonyl oxygen of FAS, respectively. (B) Distances between the carbonyl oxygen (black) and
amide hydrogen (red) of V96CDK4 and the indoyl hydrogen and carbonyl oxygen of CRB, respectively. (C) Distances between the carbonyl oxygen
(black) and amide hydrogen (red) of L83CDK2 and the indoyl hydrogen and carbonyl oxygen of FAS, respectively. (D) Distances between the carbonyl
oxygen (black) and amide hydrogen (red) of L83CDK2 and the indoyl hydrogen and carbonyl oxygen of CRB, respectively. (E) Distances between the
His95CDK4 Nd-H and the carbonyl oxygen of FAS (red) and CRB (black), respectively. (F) Distances between Lys89CDK2 amine-N and the N+/C of FAS
(red) and CRB (black), respectively.
doi:10.1371/journal.pone.0042612.g006
Figure 7. Thermodynamic Integration. Each point (200 ps window) represents the free energy ‘‘cost’’ of the carbofascaplysin to fascaplysin
transformation in the CDK4 and CDK2 complex calculated from 19 values for l. The difference (DDG0) between the two plots quantifies the energetic
contribution for selectivity that can be attributed to the positive fascaplysin charge.
doi:10.1371/journal.pone.0042612.g007
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Conclusions
The molecular modelling study in this work addresses the
remarkable selectivity of fascaplysin for CDK4. We have
established a ‘hybrid model’ approach for CDK4 as a suitable
starting point for ligand docking and molecular dynamics studies.
Thermodynamic integration focussing on the effect of the positive
charge on fascaplysin demonstrates that this charge significantly
contributes to fascaplysin selectivity, while additional factors such
as the polar interaction with His95CDK4 may also play a role.
Molecular dynamics simulations indicate that the molecular basis
of this effect may be due to an unfavourable interaction with
Lys89CDK2. Our study suggests that there is a significant gain in
specificity to be made by incorporating/maintaining a positively
charged functional group when designing inhibitors selective for
CDK4.
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